Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Eprex Stability Improvements Planned In Response To Aplasia Incidence

Executive Summary

Johnson & Johnson will seek alternative stabilizers for its erythropoietin Eprex in response to reports of pure red cell aplasia following the removal of human serum albumin from the product formula
Advertisement

Related Content

Roche View On Biogenerics: “They Will Come,” But Process Won’t Be Simple
Roche View On Biogenerics: “They Will Come,” But Process Won’t Be Simple
J&J Eprex “Best Handling Practices” Program Aims To Reduce PRCA Cases
J&J Eprex “Best Handling Practices” Program Aims To Reduce PRCA Cases
Quarterly Conference Calls, In Brief
Third Quarter Conference Calls, In Brief
Aranesp, Procrit Reimbursement Support Could Raise Kickback Issues – IG
J&J Wants Changes To Medicare OPPS Rule; Procrit Could Benefit
J&J Eprex EU Label Changed; FDA Investigating Manufacturing Fraud
J&J Eprex EU Label Changed; FDA Investigating Manufacturing Fraud
Advertisement
UsernamePublicRestriction

Register

PS040476

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel